Impact of secukinumab on patient-reported outcomes in biologic-naive patients with psoriasis in a US real-world setting

To describe real-world baseline characteristics and patient-reported outcomes (PROs) at 6-month and 12-month follow-up visits among patients with psoriasis who initiated and maintained secukinumab, stratified by prior exposure to biologics. This real-world study included patients enrolled in the Cor...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2022-11, Vol.33 (8), p.3178-3187
Main Authors: Strober, Bruce, Patil, Dhaval, McLean, Robert R., Moore-Clingenpeel, Melissa, Guo, Ning, Levi, Eugenia, Lebwohl, Mark
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal, Humanized - therapeutic use
Biological Products - therapeutic use
Humans
Patient Reported Outcome Measures
patient-reported outcomes
Psoriasis
Psoriasis - chemically induced
Psoriasis - drug therapy
registry
secukinumab
Severity of Illness Index
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To describe real-world baseline characteristics and patient-reported outcomes (PROs) at 6-month and 12-month follow-up visits among patients with psoriasis who initiated and maintained secukinumab, stratified by prior exposure to biologics. This real-world study included patients enrolled in the CorEvitas (formerly Corrona) Psoriasis Registry who initiated and maintained secukinumab through 6-month and/or 12-month follow-up. Demographics, clinical characteristics, and PROs were collected. PROs included Dermatology Life Quality Index (DLQI); itch, skin pain, fatigue, and EuroQol visual analog scales; and Work Productivity and Activity Impairment. Mean (SD) differences between baseline and follow-up visits were calculated for all outcomes. Overall, 652 patients had a 6-month follow-up visit, 460 (70.6%) were biologic experienced and 192 (29.4%) were biologic naive. Biologic-experienced and biologic-naive patients reported mean (SD) improvements in all PROs measured at 6-month follow-up. Similar improvements were seen among patients with a 12-month follow-up visit (n = 390) and both 6-month and 12-month follow-up visits (n = 326). Biologic-experienced and biologic-naive patients with psoriasis who initiated and maintained secukinumab treatment reported improvements in PROs at 6-month and/or 12-month follow-up visits. These findings suggest that secukinumab is a potential biologic for psoriasis at any point along the patient treatment journey.
ISSN:0954-6634
1471-1753
DOI:10.1080/09546634.2022.2116266